Login to Your Account

'Moving in the Tau Direction'

TauRx Launches Pivotal LMTX Program in Pick's, Alzheimer's

By Nuala Moran
Staff Writer

Wednesday, September 12, 2012

LONDON – TauRx Therapeutics Ltd. announced the start of a 180-patient Phase III trial of its tau aggregation inhibitor, LMTX, in Pick's disease, an early onset form of dementia that shows similar characteristics to Alzheimer's disease.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription